Kopran

A Global Pharmaceutical Company

Kopran

A Global Pharmaceutical Company

Bulk Drugs


API's Category Specifications Regulatory Status

Atenolol

Anti-Hypertensive

IP/BP/EP/USP

CEP, EU GMP

Amlodipine Besylate

Anti-Hypertensive

IP/BP/EP/USP

DMF Available

Metoprolol Succinate

Anti-Hypertensive

IP/BP/EP/USP

DMF Available

Metoprolol Tartrate

Anti-Hypertensive

IP/BP/EP/USP

DMF Available

Roxithromycin

Macrolides

IP/BP/EP

CEP, KFDA

Azithromycin

Macrolides

IP/BP/EP/USP

CEP

Clarithromycin Granules 27.5%

Macrolides

In-House

DMF Available

Clarithromycin Granules 33%

Macrolides

In-House

 

Clarithromycin Granules 43%

Macrolides

In-House

DMF Available

Pregabalin

Neuromodulator

IP/EP/In-House

EU DMF available and CEP applied

Ceftriaxone Sodium

Sterile Cephalosporins

IP/BP/EP/USP

DMF Available

Cefotaxime Sodium

Sterile Cephalosporins

IP/BP/EP/USP

DMF Available

Cefepime (with L-Arginine) for Injection

Sterile Cephalosporins

IP/USP

 

Meropenem (with Sodium Carbonate) for Injection

Carbapenems

IP/USP

DMF Available

Doripenem

Carbapenems

In-House

DMF Available

Biapenem

Carbapenems

In-House

DMF Available

Lymecycline

Anti-Acne,

Anti-Infective

EP

 

Nitroxoline

Urological

In-House

 

Ticagrelor

Anti-Thrombotic

IP / In-House

 

Pellets Category

Duloxetine Pellets 17%, 21.5%

Anti-Depressent

Esomeprazole Pellets 8.5%, 15%, 22%

Anti-Ulcerant

Venlafaxine Pellets 33%, 42.7%

Anti-Ulcerant

API's Category R&D Sample availability R&D Tech pack availability Specifications

Apixaban

Anti-Thrombotic

Apr.2018

May.2018

In-House

Dabigatran Etexilate Mesylate

Anti-Thrombotic

May.2018

June.2018

In-House

Rivaroxaban

Anti-Thrombotic

Apr.2018

May.2018

In-House

Canagliflozin

Anti-Diabetic

Jul.2018

Aug.2018

In-House

Dapagliflozin

Anti-Diabetic

Sep.2018

Oct.2018

In-House

Empagliflozin

Anti-Diabetic

Nov.2018

Dec.2018

In-House

Chlorthalidone

Anti-Hypertensive

Sep.2018

Oct.2018

EP/USP

Hydroxychloroquine Sulphate

Anti-Malarial

Sep.2018

Oct.2018

USP

Tebipenem

Carbapenems

Apr.2018

May.2018

In-House

Imipenem  (Non-Sterile )

Carbapenems

May.2018

Jun.2018

USP

Ertapenem

Carbapenems

May.2018

Jun.2018

In-House

Faropenem

Carbapenems

Aug.2018

Sep.2018

In-House

Citicoline Sodium

Central Stimulant

May.2018

Jun.2018

In-House


Note


  • Products will not be offered for sale in countries where valid Patents are in force.
  • Information on CRAMS : We do contract manufacturing for various companies for UK, Australia, Canada and other European markets. ( to be added after the product list)
  • It is the responsibility of the buyer to comply with the above.


For more information on Finished Dosage Forms, send an e-mail to: api@kopran.com